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ABSTRACT 
The Relationship between the Level of Antibiotic Use and Resistance among Enteric 
Bacteria in a Multi-site Integrated Human and Swine Population.  (May 2008) 
Kristi Lynn Christian, B.S., Texas A&M University 
Chair of Advisory Committee:  Dr. H.M. Scott 
 
 
 The objective of this longitudinal study was to study the relationship between 
changes in prevalence of resistant enteric bacteria associated with mean monthly doses 
(MMD) of various antibiotics used in each of two host species.  From January 2004 – 
January 2007, monthly composite swine fecal samples and human wastewater samples 
representing various production and occupational cohorts, respectively, were collected 
from 19 geographically unique locations in east- and south-central Texas.  Bacterial 
isolates cultivated on CHROMagar-E.coliTM and DifcoTM mEnterococcus (ME) were 
tested for susceptibility to multiple antibiotics by microbroth dilution using the 
SensititreTM system.  The relationship between the prevalence of resistant bacteria, 
sampling period, and antibiotic use within each host species was assessed in a 
generalized linear model adjusted for the dependence of responses within location using 
a binomial distribution and logit link function in STATA® ver. 9.2. 
 For the swine E. coli isolates, the relationship between tetracycline resistance and 
level of chlortetracycline (CTC) use in swine illustrated a dose-response relationship, 
   iv
 
  
with odds ratios (OR) of 1.20 and 1.81 (P < 0.05) for second- and third-level categories 
of MMD relative to baseline (zero-use) respectively.  When considered by swine 
production groups, intake boar isolates had an elevated relative odds of resistance to 
tetracycline (OR = 1.51, P < 0.05), and the nursery units had an elevated odds (OR = 
2.61, P < 0.05) of exhibiting resistance to ceftiofur, relative to pigs housed in the 
farrowing barns.  Regarding swine Enterococci isolates, those swine from locations that 
utilized tylosin had an elevated OR of 3.54 (P < 0.05) of exhibiting resistance to tylosin, 
relative to those locations that used no tylosin. At this juncture, an apparent occupational 
risk of harboring tetracycline-resistant E. coli, and the apparent sparing effect 
(Enterococcus spp.) associated with exposure to swine production, remain unexplained. 
This study demonstrated that the prevalences of tetracycline- and tylosin-resistant 
enteric bacteria swine were dependent on CTC and tylosin use in feed, respectively.  
Swine production group-effects on the prevalence of tetracycline, ceftiofur, and 
erythromycin resistance were also important.  This study provides a better understanding 
of the relationships between antibiotic prescribing practices at the ecologic level and the 
relative odds of carriage of resistant bacteria within two host species in a vertically 
integrated agri-food system.     
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CHAPTER I 
INTRODUCTION 
 
Antibiotics1 were first identified and introduced into use in the early twentieth 
century.  Antibiotics are natural or synthetic compounds that either kill or inhibit growth 
of bacterial microbes that can cause disease in humans or animals (Centers for Disease 
Control and Prevention, 2006).  Antibiotic resistance is the ability of a bacteria to grow 
in the presence of an antibiotic that would normally kill or inhibit its growth.  The net 
result may be to reduce the effectiveness of drugs, or other agents to cure or prevent 
infections.  The first documented reports of clinically relevant  antimicrobial resistance 
to sulfonamides appeared in 1939, to penicillin in 1942, and to streptomycin in 1946 
(MacLean et al., 1939; Fleming, 1942; Klein et al., 1946).  Development of resistance to 
antibiotics has become one of the most pressing international public health concerns 
(Centers for Disease Control and Prevention, 2006).  Antibiotic resistance is a leading 
concern for agencies such as the Centers for Disease Control and Prevention (CDC), the 
United States Department of Agriculture (USDA), as well as the Food and Drug 
Administration (FDA) which regulates the approval, marketing, and use of antibiotics in 
both human and animal populations in the United States.  A recent and well-known 
This thesis follows the style of Preventive Veterinary Medicine. 
1 An antibiotic is a drug used to kill or inhibit bacterial growth and may be considered one of the 
antimicrobial agents.  Antimicrobial is a general term for drugs, chemicals, or other substances that kill or 
slow the growth of microbes. 
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example of the association of antibiotic use in farm animals on resistance levels in the 
animal and human populations is the temporal link between avoparcin approval in the 
poultry industry in Europe, and the resulting increase of vancomycin-resistant 
Enterococci (VRE) in the European poultry and human populations (Wegener et al., 
1999).  This finding, among others, resulted in the animal-health formulation of the 
product being withdrawn from the market in Europe (Wegener et al., 1999).  It is 
important to note that avoparcin was never approved for use in North America, and VRE 
remain exceedingly rare in the North American livestock and poultry populations (Poole 
et al., 2005).  Recent reports have prompted the development of programs to educate 
both the public and health-care providers (human and animal) on prudent use guidelines 
for the treatment for infections with antibiotics (McDonald et al., 1997; van den Bogaard 
et al., 2001).  Some authors contend that inappropriate and repeated use of antibiotics in 
human medicine is primarily responsible for the rise in resistant bacteria (Centers for 
Disease Control and Prevention, 2005b).  The CDC have estimated that in the United 
States nearly 90,000 people die each year from infectious diseases with 70% of these 
caused by bacteria that are resistant to at least one commonly used drug (Centers for 
Disease Control and Prevention, 2005a). 
 The use of antibiotics for nontherapeutic purposes in healthy animals in order to 
promote growth or prevent disease is heavily debated, as it is believed that the 
agricultural use of these drugs has resulted in pressures selective for the emergence of 
resistant bacteria.  These bacteria or their genetic material encoding for resistance may 
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then be transferred to humans through the food supply, by direct contact with animals, or 
via waste runoff from animal production facilities.  In the year 2000, the World Health 
Organization (WHO) recommended the ban of antibiotics in food animals for 
nontherapeutic purposes, unless a risk-based evaluation proved their safety (WHO, 
2000).  Although antibiotics have been approved for growth promotion and improved 
feed efficiency in the U.S., there is no centralized reporting system useful for relating the 
quantity of antibiotic use in food animals and the level of resistance in human food 
consumers.  International organizations such as the Food and Agriculture Organization 
(FAO) of the United Nations, the Office International des Épizooties (OIE: World 
Organization for Animal Health), and the WHO have recognized this problem and 
recommend that each country establish a monitoring system (Nicholls et al., 2001; 
WHO, 2001).  Systems that may be used by agencies to monitor levels of resistance 
alongside antibiotic use may be useful in answering questions concerning the quantities 
of antibiotics used in the food animal industry and their effect on resistance levels.  
Public concern about the potential effects of antibiotic use in farm animals on the 
levels of resistance in enteric bacteria colonizing the human population – particularly 
pathogenic enteric bacteria - has led to increased research in this area.  For example, in 
the United States, fluoroquinolone-resistant Campylobacter spp. have been linked to 
flouroquinolones used in treatment of respiratory diseases in poultry.  The strains found 
in poultry were very similar to those found in humans leading the researchers to 
hypothesize that fluoroquinolone use in poultry was a major contributing factor  
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(Anderson et al., 2003).  Another research effort to compare enteric bacterial strains of 
animal and human origins found identical blaCMY-2 genes in resistant E. coli and 
Salmonella spp. isolates from cattle, swine, and human samples (Winokur et al., 2001).  
Although identical genes in resistant bacteria have been found, it has not been 
definitively proven that transmission (and subsequent colonization) between host species 
can (or have) taken place as a direct result of antibiotic use in food animals. 
 In response to multiple study findings and evidence regarding the relationship 
between antibiotic use in food animals and the rise in resistance of enteric bacteria of 
both human and animal origins, the National Antimicrobial Resistance Monitoring 
System (NARMS) for enteric bacteria was created in 1996 in order to better monitor the 
levels of resistance in enteric bacteria (Centers for Disease Control and Prevention, 
2007).  NARMS is a collaboration of the CDC, the FDA (Center for Veterinary 
Medicine) and the USDA (both the Food Safety and Inspection Service (FSIS) and the 
Agricultural Research Service (ARS)).  NARMS is responsible for testing and recording 
the resistance results for non-Typhi Salmonella isolates, Salmonella Typhi, Shigella, and 
E. coli O157:H7 isolates received from participating public health departments and a 
variety of veterinary sources.  The information gathered is used to evaluate trends in 
resistance in order to better guide the development of regulatory policies regarding the 
use of drugs in food producing animals (Centers for Disease Control and Prevention, 
2004). 
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To aid in evaluating the trends in resistance levels within and among human and 
food-animal populations, longitudinal studies may be employed.  It is presently difficult 
to evaluate the association of antibiotic use in the food animal populations with levels of 
resistance in the human population due to high human mobility, multiple and disparate 
sources of food (specifically, meat, milk and poultry products), and lack of antibiotic 
usage data.  Since bacterial resistance may also arise due to physicians’ over-prescribing 
of antibiotics and individual patient non-compliance or antibiotic abuse, it is problematic 
to assume that antibiotic use in food animals is the major contributing factor to 
resistance levels.  Scientific studies need to be conducted in order to better assess this 
relationship, beginning with more carefully defined and closed populations, with known 
sources of occupational and food exposure to enteric bacteria, and with more accurate 
antibiotic use data from both the animal and human populations. 
Objectives 
This study is one component of a large-scale 3-year multi-site longitudinal 
project and is specifically designed to investigate the temporal and spatial relations 
between the levels of antibiotic-resistant phenotypes and genotypes of generic and 
pathogenic enteric bacteria (specifically Escherichia coli (E. coli), various Salmonella 
enterica serovars, and Enterococcus spp.), and concurrent antibiotic use in both swine 
and human species.  The specific objectives of this longitudinal study are to: 1) examine 
the antibiotic resistance phenotypes of certain commensal enteric bacteria (specifically 
E. coli and Enterococcus spp.) isolated from aggregated monthly wastewater samples 
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from humans and composite fecal matter from swine, and 2) to study the relationship 
between the prevalence proportion of these resistant bacteria and the amount and type of 
antibiotics used in both host species (i.e., varying by host, occupational or production 
cohort, month or season, and geographical location).  The benefits of our research 
pertain to a better understanding of the relationships between antibiotic prescribing 
practices at the ecologic level (in both humans and swine) and the relative odds of 
carriage of resistant bacteria within and among host species in a vertically integrated 
agri-food system. 
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CHAPTER II 
LITERATURE REVIEW 
 
Introduction to Antibiotics 
Before the introduction of antibiotics, human and veterinary medical 
practitioners had limited options when dealing with bacterial infections.  The beginnings 
of clinical application of antibiotics in the 1930’s and 1940’s ushered in a new era of 
progress in medicine, but along with this progress a new problem of resistance arose 
(Harris and Kahn, 1940; Lowell et al., 1940; McKee and Rake, 1942).  Antibiotics were 
becoming less affective in killing of inhibiting bacterial growth.  Over the next 60 years, 
the number of resistant bacterial strains steadily increased, recently culminating in the 
WHO listing antibiotic resistance (AR) as a leading world health issue (Centers for 
Disease Control and Prevention, 2006).    
Antibiotics work by interfering with various bacterial functions, such as cell wall 
synthesis, protein synthesis, and nucleic acid synthesis (Bonafede and Rice, 1997; Witte, 
1998; Tenover, 2006).  Bacteria may become resistant through spontaneous mutation or 
else acquire resistance through a number of sexual- and asexual-reproductive and other 
genetic mechanisms.  After acquiring resistance, the bacteria may pass from human to 
human, animal to animal, or from food animals to humans through the food chain 
(Anderson et al., 2003).   
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Selection pressures, such as those provided by antibiotic use, can improve the 
probability of survival and propagation of resistant bacterial strains.  When bacteria are 
initially introduced to antibiotics, the susceptible bacteria die resulting in a population 
consisting only of those bacteria that express resistance.  In a Swedish study, scientists 
conducted a cohort study in order to investigate the effects of antibiotic treatment over a 
1 year period on commensal flora in humans (Gustafsson et al., 2003).  A significant 
increase (P = 0.0001) in rifampicin resistance was observed for E. coli in patients with 
antibiotic treatment over a one year period compared to those patients with no antibiotic 
treatment.  Although this study does support the hypothesis that bacteria with a high 
mutation rate are heavily influenced by exposure to antibiotics, study limitations 
included that many of the patients exhibited compromised immune systems.  Bacterial 
mutation and proliferation may have been reduced in patients with non-compromised 
immune systems.  Selection pressures can also include environmental conditions.  A 
study conducted with Belgian fattening pigs found a significant association of AR with 
pen hygiene (Dewulf et al., 2007).  This finding supports the selection pressure 
hypothesis.  According to this theory, susceptible bacteria could have been more readily 
removed during cleaning, allowing the resistant bacteria to multiply and become the 
dominant strains.   
Mutation is not the only mechanism through which bacteria acquire resistance to 
antibiotics; they may also receive and transfer resistance genes to other bacteria; both 
within and between species (Tenover, 2006).  One example of a bacterium that is able to 
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both receive and transfer genetic resistance is Escherichia coli.  As coded through these 
genetic elements, bacteria may generate enzymes that destroy the antibacterial agent, 
develop pumps that eject the agent, change the cell wall so there are no binding sites, or 
mutate so the agents are unable to reach the target site (Tenover, 2006). 
Aside from the selective pressure applied by antibiotic use, one study also found 
an association between population density and antibiotic resistance (Bruinsma et al., 
2003).  The researchers considered three different cities and measured the defined daily 
dosages (DDD) per 1,000 inhabitants by square mile.  Adjusted for DDD, the highest 
prevalence of antibiotic resistance was found in the city with the highest density.  This 
study had several potential confounding limitations including; city location (located on 
different continents), antibiotic recording systems (recorded in different years), low 
response rates, and other forms of selection bias.  Further studies need to be conducted to 
provide better insight into the population density theory.  Unique units within the same 
geographic area, but with different population densities need to be considered instead.  
In addition, a consistent system of antibiotic dispensing records should be used to give a 
more accurate account of DDD.  If the assumption is that population density influences 
antibiotic resistance, then the most populated units should have the highest level of 
resistance, all other factors (i.e., DDD) being held constant.   
Escherichia coli 
Escherichia coli (E. coli) are facultative anaerobes and are part of the normal 
intestinal flora in humans and animals (Schroeder et al., 2002a).  The intestinal flora play 
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an important role in the immune response, food digestion, and prevention of the 
colonization of the intestinal tract by pathogens (Gustafsson et al., 2003).  The E. coli 
bacterium belongs to the Enterobacteriaceae family and is ubiquitously found in the 
feces of healthy humans, swine, and other domestic and wild mammals and birds.  Some 
pathogenic strains of E. coli are responsible for several infectious diseases in humans 
(e.g. urinary tract infections, neonatal meningitis, septicemia, and surgical site 
infections) (Schroeder et al., 2002a).  Since commensal (non-pathogenic) E. coli are 
highly prevalent, and are easily isolated in the feces of healthy humans and animals, they 
are commonly used as indicator bacteria (Scott et al., 2005).  The differences in 
prevalence of resistance to one or more antimicrobials (within and among host species) 
may be used to assess the short- and long-term effects of variable selective pressures 
applied in those same host communities (O'Brien, 2002; Schroeder et al., 2002b). 
The spread of resistant E. coli between host-species suggests that bacteria 
harboring the resistance genes may spread from food-producing animals to humans.  
Escherichia  coli exposure of humans may occur via fecal contamination of carcass meat 
during food animal slaughter, or via direct contact with the animals (Piddock, 1996; Van 
Den Bogaard and Stobberingh, 2000; Scott et al., 2005; Dewulf et al., 2007).  Studies to 
research this link have been conducted in Spain and Taiwan where E. coli strains with 
reduced quinolone susceptibility were found in both humans and poultry.  Since 
quinolones are not used in treatment for children, the reduced susceptibility found in 
these studies raised concerns of the transfer of resistance through the food chain 
   11
 
  
(O'Brien, 2002).  Other studies have found that the use of certain drugs such as 
penicillins, sulphonamides, cephalosporins, and tetracyclines greatly influences the 
relative proportions of AR E. coli in feces (Huycke et al., 1998; Bonten et al., 2001).     
Enterococcus spp. 
Enterococci are gram-positive facultative anaerobes and are commonly found in 
the intestinal tracts of healthy humans and animals (Murray, 1990).  Enterococci may 
cause endocarditis, bacterimia, urinary tract infections, neonatal infections, and other 
nosocomial infections (Murray, 1990).  The Enterococcus genus contains many strains 
that are almost completely resistant to antibiotics (DeLisle and Perl, 2003). 
Because enterococci are often resistant to many antibiotics, one treatment 
reserved almost exclusively for enterococcal and staphylococcal infections is the 
antibiotic vancomycin, often used in combination with other antibiotics.  Unfortunately, 
in the late 1980’s, reports of vancomycin resistance began to surface and the health care 
community has since had to reassess enterococcal therapy.  Newer and more powerful 
drugs must now be employed in cases where vancomycin resistance is present.  The first 
reports of vancomycin-resistant enterococci (VRE) in the United States were in 1988, 
when researchers found resistant strains in infected hospital patients and one 
asymptomatic hospital patient (Uttley et al., 1988).  By 1997, more than 15% of 
nosocomial infections in U.S. hospitals were caused by VRE (Wegener et al., 1999).  
Although the spread of VRE in Europe is believed to be a result of the use of avoparcin 
in food-animal populations, studies have indicated that in the United States VRE may be 
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transferred from the hospital environment to the human community (Wegener et al., 
1999; DeLisle and Perl, 2003).  Since the European ban of avoparcin in 1997, studies 
have found a high prevalence of VRE in pig feces and slurry (Manero et al., 2006).  This 
led to the hypothesis that the past use of tylosin as a feed additive may have selected for 
vancomycin resistance genes retarding the rate of decline of VRE prevalence despite the 
ban.    
Non-therapeutic and Therapeutic Antibiotic Usage in Food Animals 
In the early 1970’s an important study found resistant E. coli not only in the feces 
of hospital patients, but also in the feces of healthy humans, animal carcasses in the 
slaughter plant, and hospital food (Cooke et al., 1971).  These findings introduced the 
idea of resistance transfer from food animals to humans.  Antibiotics have been used in 
the food-animal industries for roughly 50 years and the effects of this use continue to be 
examined. 
  Some scientists hypothesize that those antibiotics used in food animals that have 
a human analog may be responsible for the increasing AR found in human populations 
(Anderson et al., 2003).  Resistant bacteria may pass to agricultural workers through 
direct contact with animals or their feces, or to the consumer through the food chain.  In 
1983, nourseothricin was introduced as a growth promoter in the German swine 
industry.  Before the introduction of nourseothricin, the prevalence of resistant E. coli in 
human and animals was extremely low.  By 1985 nourseothricin resistance was found in 
pigs, and by 1990 the resistance had been found in pig farmers, their families, and in 
   13
 
  
hospital patients (Witte, 1998).  In 2005, a study conducted at slaughter plants in Great 
Britain found multiple cephalosporin-resistant E. coli strains in cattle feces, and recently, 
extended-spectrum cephalosporin resistance in humans also has been found (Winokur et 
al., 2001; Schroeder et al., 2002a; Batchelor et al., 2005).  Ceftiofur is the only 3rd 
generation cephalosporin approved for use in food animals (in 1988, the FDA approved 
ceftiofur for use in cattle and in 1992 it was approved for use in swine in the United 
States) and these data suggest the possible transfer of resistant E. coli from food animals 
to humans.  A high rate of resistance to other antibiotics such as gentamicin, tobramycin, 
streptomycin, tetracycline, trimethoprim-sulfamethoxazole, and chloramphenicol was 
also found.   
As mentioned earlier, another European example of resistant bacterial transfer 
from animals to humans is the VRE.  Genetically similar strains were isolated from 
animals and humans, thus suggesting that resistant bacteria may be transferred across 
species (DeLisle and Perl, 2003).  In the south of The Netherlands, highly resistant VRE 
were isolated from turkeys, turkey farms, turkey slaughterers, and urban residents 
(Stobberingh et al., 1999).  Fecal samples were taken from individual farmers, turkeys, 
slaughterhouse workers, and residents to be tested for VRE levels.  Although one farmer 
and his flock shared an indistinguishable VRE strain, showing that animals and humans 
may carry the same clone, an additional finding of interest was that the strains were also 
resistant to quinupristin-dalfopristin.  This antibiotic is a combination of streptogramins 
B and A and has been therapeutically used in human medicine in The Netherlands. 
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In 1999, owing to public and political pressure to decrease the amount of 
antibiotics used in food animals, the Danish poultry industry and swine industries 
voluntarily discontinued the use of antimicrobial growth promoters (AGPs).  As a result 
of discontinuing AGPs, poultry producers have seen an increase in leg and skin 
problems (Casewell et al., 2003).  The Danish pork industry has also seen negative 
impacts in mortality and weight gains.  Although an overall reduction in antibiotic use 
has been observed, Danish veterinarians have resorted to using therapeutic antibiotics 
more regularly to combat increasing morbidity rates (Casewell et al., 2003). 
Classes of Antibiotics 
 The antibiotics are grouped into classes based on chemistry, mode of action, and 
other properties.  Penicillins are an example of a β-lactam antibiotic that works by 
inhibiting bacterial cell wall synthesis.  This class is grouped into several 
subclassifications based on their ability to cross the cell wall and adhere to the penicillin 
binding proteins (PBPs) (Howland and Mycek, 2006).  The subclassifications are as 
follows:  β-lactamase-sensitive penicillins, β-lactamase-resistant penicillins, β-
lactamase-sensitive penicillins with extended spectra, β-lactamase-protected penicillins, 
and carbapenems (Bush et al., 1995).  Bacteria may become resistant to penicillins by 
altering PBPs, decreasing the cell wall permeability, or by producing β-lactamase 
enzymes. 
Cephalosporins, also beta-lactam antibiotics, interfere with bacterial cell wall 
synthesis and are commonly used in human medicine (Howland and Mycek, 2006; 
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Tenover, 2006).  One way to categorize cephalosporins is based on when they were 
discovered and their spectrum.  There are four categories of cephalosporins: first-
generation, second-generation, third-generation, and fourth-generation.  The first-
generation cephalosporins are very effective against Gram-positive bacteria, but less 
effective against Gram-negative bacteria (Williams et al., 2001).  The second, third, and 
fourth generations of cephalosporins are effective against both Gram-positive and Gram-
negative bacteria.  Bacteria may become resistant to cephalosporins by altering the 
permeability barrier, changing the structure of the binding site, or by producing enzymes 
that destroy the drug (cephalosporinases or beta-lactamases). 
Aminoglycosides inhibit protein synthesis in aerobic Gram-negative bacilli.  
Resistance to aminoglycosides may develop by altering the ribosomal binding site or 
through a lack of porin channels to transport the drug across the cell membrane. Two 
other antibiotic classes that inhibit protein synthesis by binding to the bacterial ribosome 
are the macrolides and tetracyclines (Tenover, 2006). 
Antibiotics belonging to the tetracycline class may act on bacteria by inhibiting 
protein synthesis (Tenover, 2006).  Since bacterial ribosomes are structurally different 
than those found in eukaryotic cells, the tetracyclines may selectively effect the bacterial 
growth in a host.  The bacteria also may become resistant to tetracyclines by developing 
efflux pumps that eject the antibiotic before it reaches the target site. 
Sulfonamides act as competitive inhibitors by binding to dihydropteroate 
synthetase and inhibiting folic acid synthesis (Howland and Mycek, 2006).  In order to 
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overcome the competitive inhibitor, bacteria may overproduce para-aminobenzoic acid, 
or else alter the enzyme binding site.  The Gram-negative bacteria, such as E. coli, may 
transfer resistance via plasmids; plasmid-mediated sulfonamide resistance is often linked 
to the use of ampicillin and tetracycline (Bean et al., 2005). 
Quinolones affect the bacterial DNA replication process by targeting the DNA-
gyrase enzyme and disrupting the DNA structure.  Bacteria develop resistance by 
changing the enzyme target site (Poirel et al., 2005). 
Future Prevention 
Most research has indicated that the critical risk factor for resistance is antibiotic 
use. Currently, the FDA encourages food animal producers to create an antibiotic 
recording system.  Although a mandatory reporting system is not in place, the U.S. 
National Pork Board has taken steps to educate pork producers on how to safely, 
effectively and efficiently use antibiotics (National Pork Board, 2007).  One program is 
the Pork Quality Assurance Program (PQA) that was created in 1989 to improve 
management practices and increase awareness of food safety.  The PQA program is a 
voluntary program, but most packers required that producers complete PQA level III 
certification as a pre-requirement for purchase of slaughter hogs.  In June 2007, the 
PQA-Plus program was launched, which includes extensive animal welfare education for 
the producers and on-site assessment.  On farms that have had producers complete the 
PQA Plus program, random audits (through the lottery system) will be conducted by a 
third party.  PQA Plus recertification and on-farm assessments will be repeated at least 
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every 3 years.  The PQA and PQA-Plus programs have introduced important principles 
and guidelines that in the future are expected to be observed by all U.S. pork producers. 
Although public attention has been focused on antibiotic use in food animals, the 
human health care system must also accept responsibility.  In the United States, patients 
expect and request antibiotics in cases where they may not be appropriate such as viral 
infections, both of which suggest a need for better patient education programs.  The 
positive effect of patient education programs was realized in a 2001 pediatrics study.  
Parents of children under 4 years of age participated in community-wide educational 
programs focused on appropriate antibiotic use.  The population that participated in the 
programs saw a decline in parents who expected but did not receive an antibiotic for 
their child and also a decrease in the percentage of parents who changed physicians as a 
result of not receiving an antibiotic (Trepka et al., 2001).  Whether this decline in usage 
translates into a decline in levels of resistance was not, however, determined.  Healthcare 
providers also need to curtail antibiotic use and only prescribe when needed, not simply   
to placate or pacify the patient.  Unnecessary prescribing was seen in a study conducted 
in Kentucky, which found that 60% of patients seen for the common cold were 
prescribed an antibiotic (Mainous et al., 1996).  Since the majority of antibacterial agents 
are prescribed in the community setting (an estimated 70%), it is extremely important 
that health care providers and patients responsibly prescribe and use these agents (Carrie 
and Zhanel, 1999). 
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The use of antibiotics in humans and animals and the effects on resistance levels 
is an international public health concern.  The potential for transfer of antibiotic–
resistant bacteria from food animals to humans is an issue that must be better studied in 
order to improve on-farm practices, decrease the level of resistance, and reduce risks to 
both animal and human health.  This research project will address the association of 
antibiotic use with the prevalence of AR bacteria in a semi-closed and integrated 
population of humans and animals. 
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CHAPTER III 
MATERIALS AND METHODS 
 
Human Study Population  
The aggregate cohorts of humans, housed in 19 geographically separate units, 
represented the study population for this project because the monthly antibiotic 
dispensing records were accessible and there was relatively limited human movement in 
and out of, as well as and across units. In each of the 19 units, multiple manhole samples 
from which to draw monthly wastewater (fecal matter) samples were strategically 
selected.  These manholes were selected based on location, to represent (where 
appropriate) relationships to hospitals, kitchens, lavatories draining various housing 
dormitories, and agricultural worker housing facilities.  Fecal samples arising from 
human wastewater collection are aggregated samples that cannot be traced to any 
individual.  
Antibiotic Records 
Typically, antibiotics were dispensed in the human population either by 
physicians at unit clinics or physicians at in-patient hospitals; the former either requiring 
patients to report directly to the clinic each day for dispensed medication or else 
permitting the patient to carry the antibiotic on their person.  Each script was written, 
entered into a centralized computer system, filled by the central pharmacy, and then 
shipped to the unit within 24 hours (see Figure 1, Appendix A).  The antibiotic class, 
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length of usage, and daily dose was logged into the mainframe computer.  We requested 
the utilization records (aggregated across prescriptions, within drug code, by unit and 
housing cohort and with patient identifiers stripped from the records) for all medicines 
with any of the specified antibiotics as the active ingredient.  These medicines were 
assigned identification numbers by the central pharmacy.  Since there are numerous 
different medications, we requested a query of the mainframe computer for antibiotics 
known to have been used between January 2004 – January 2007.  An example of such a 
search is as follows: erythromycin has the pharmacy identification code of 00064-3000.  
We requested dosage information, length of treatment, route of administration, major 
drug class, and finally, records concerning unused medications returned to the pharmacy 
by unit clinics/hospitals during the noted timeframe.   
The formula for mean monthly dosages (MMDs) in the human population was as 
follows:  
 
total amount of antibiotic used (g) 
MMDH =   
[total number of population at risk in a category (i.e., animal worker vs. 
non-animal worker) in the unit × average body mass of a person at risk 
(kg)] × 1 month 
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The average body weight of a person at risk was taken from a 2004 study conducted by 
the U.S. Department of Health and Human Services.  During the period of 1999-2002, 
the mean mass of men in the United States over the age of 20 was 86 kg (Ogden et al., 
2004). 
For analytic purposes, we grouped the antibiotics by class and used the aggregate 
data by month.  As explanatory variables, these were treated first as a ratio relating the 
total mass (g) of an antibiotic utilized in a month at any given unit to the number of 
humans housed in the unit for that month. 
A secondary coding of these aggregated antibiotic usage data related the mean 
monthly dosage (MMDs) per category of population at risk (agricultural worker or 
nonagricultural-worker), of an antibiotic class, relative to the overall human population 
in that category.  The first ratio spread the effect of antibiotic selection pressure across 
the entire population, whereas the latter ratio spread the effect of antibiotic selection 
pressure across the category of population at risk that were prescribed the product.  
While both ratios are potentially correlated to some degree, it is possible that a relatively 
few individuals received a large proportion of the antibiotics, such that the selection 
pressure was not spread across the entire population’s enteric flora.   
Swine Study Population 
There were 12 units that housed swine, with very limited movement of breeding 
swine into the system, and no pork products leaving the system except for waste 
byproducts after slaughter.  A very small percentage of nursery/grower/finisher swine 
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were sold and exited the system due to poor growth performance.   Monthly floor fecal 
samples were collected from the aggregate swine population at each unit (5 farrow-to-
finish units and 7 grower-to-finish units).  Antibiotics were distributed to the swine 
through the feed supply or directly administered via parenteral or oral routes (see Figure 
2, Appendix A).  We considered the feedgrade and injectable antibiotics separately for 
analysis.  There was no formal antibiotic reporting system for actual use or 
administration in the food animals; therefore, we utilized the monthly listing of 
feedgrade antibiotics used (via formulations) and monthly antibiotic 
purchasing/dispensing records.  The mean monthly dosages (MMDs) for swine were 
calculated as follows:  
total amount of antibiotic used (g) 
MMDS =   
  [total number of pigs in a unit × average body mass of a pig (kg)]  
  × 1 month 
 
We also considered the MMDs according to the swine categories: 
grower/finisher, nursery pigs, gestating and farrowing females and piglets2, and boars; 
each with the average body mass adjusted accordingly.  The average body mass for each 
  
                                                          
2 The figure heading ‘Farrowing pigs’ and table heading ‘Farrowing’ includes gestating and farrowing 
females and piglets. 
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swine category was estimated by an experienced veterinarian from Texas A&M 
University College of Veterinary Medicine and Biosciences. 
Sampling Method 
 The trained environmental compliance staff member for each designated unit 
directly supervised the monthly wastewater sample collection (February 2004 through 
January 2007 inclusive).  Following collection, samples were stored in a refrigerator 
until the technician arrived for the scheduled pickup.  Our contracted laboratory courier 
service transported samples to a central facility, stored them refrigerated at 4ºC, and then 
shipped  each of the samples in a 100 ml sterile container to the USDA-ARS facility in 
College Station, TX for further processing. 
 A swine veterinarian from the College of Veterinary Medicine and Biomedical 
Sciences at Texas A&M University collected at least thirteen (range: 13-25) aggregated 
monthly swine fecal samples from each of the five farrow-to-finish units.  In addition, at 
least four samples (range: 4-8) and two samples (range: 2-5) were collected each month 
from six, and one, grower-finisher units, respectively (7 units total).  Each time the 
boar/gilt isolation site was occupied (about 3 times per year), individual (boar) and 
aggregate (gilt) sampling was performed.  These samples were held in iced coolers and 
transported to USDA-ARS laboratories in College Station, TX for analysis. 
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Laboratory Analysis 
 Once the wastewater and fecal samples arrived at the laboratory they were 
logged and recorded by unit, manhole (for swine: pen number and production category), 
and date.  Each original wastewater sample was thoroughly mixed and then divided into 
five 5 ml tubes as follows: three of the tubes received 4 ml of sample aliquot, in addition 
to being pre-filled with 1 ml of glycerol.  The remaining 38 ml of sample were 
centrifuged for 20 minutes at 3200 rpm and the supernatant removed.  The remainder 
was divided into two 5 ml vials.  All five 5 ml tubes were frozen at -72°C.  Each swine 
fecal sample was dispensed into five 5 ml tubes as follows: three of the tubes received 1 
ml of glycerol and 4 ml of the fecal sample.  The two remaining 5 ml tubes were filled 
with 5 ml of the swine fecal sample, and all five 5 ml tubes were frozen at -72°C. 
Later, a single wastewater vial (with glycerol) was thawed in a 37°C water bath 
and subjected to enrichment and selective growth as follows.  After thawing, 1 ml of 
sample was mixed with 9 ml of tryptic soy broth (TSB) and incubated at 37.5°C for 24 
hours.  Following incubation, 0.1 ml of the product was streaked onto CHROMagar-
E.coli™ (DRG International, Mountainside, NJ) agar and DifcoTM mEnterococcus agar 
(ME) (Becton Dickinson, Sparks, MD).  The presumptive E. coli isolates were further 
incubated at 37.5°C for 24 hours, and the Enterococci were incubated at 45°C for 48 
hours.  Following incubation, a single E. coli colony (blue, smooth colony) was chosen 
to streak to a sheep-blood agar plate and was then incubated at 37.5°C for 24 hours.  
After incubating the Enterococci for 48 hours, a single colony (dark purple with a gold 
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sheen) was chosen to streak a blood agar plate and incubated at 37.5°C for 24 hours.  
The same two procedures for cultivating E. coli and Enterococci were followed for the 
swine fecal samples, except that the samples were not subjected to pre-enrichment with 
TSB.   
Phenotypic Resistance Characterization 
 E. coli were tested for antibiotic susceptibility using microbroth dilution where 
minimum inhibitory concentrations (MIC) against 15 antibiotics (see Table 1, Appendix 
B) were determined. The Enterococcus spp. were also tested for antibiotic susceptibility 
using microbroth dilution where MICs against 17 antibiotics were determined (see Table 
2, Appendix B).  MIC values were interpreted according to prescribed Clinical 
Laboratory Standards Institute methods (formerly NCCLS) (National Committee for 
Clinical Laboratory Standards, 1999).  Testing was completed on the Sensititre™ (Trek 
Diagnostics Inc., Cleveland, OH) 2003 NARMS test panel designed by the National 
Antimicrobial Resistance Monitoring System (NARMS), a jointly funded project of 
CDC, USDA and FDA. 
Statistical Analysis 
The antibiotic data were aggregated by month and descriptive statistics for each 
unit and host-species were calculated.  In addition, appropriate ratios for antibiotics 
utilized in a month at any given unit and mean monthly dosages (MMDs) and dose 
categories were calculated for both host species.  Histograms were constructed to 
illustrate the MMDs across all swine and human units, respectively.  A few of the 
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antibiotics studied were used very sparingly in the study populations; these antibiotics 
were assessed further on a use versus nonuse basis.  Those antibiotics were ceftiofur, 
tylosin, and tilmicosin in the swine population, and ciprofloxacin in the human 
population. 
In order to assess the effect of MMDs on tetracycline resistance in the E. coli 
isolates in the swine study population, the MMDs were considered in three categories 
based on the histogram of distribution for the MMDs.  The majority of the swine were 
not prescribed chlortetracycline; the isolates collected from these swine were considered 
in the zero-use category.  The isolates collected from the swine prescribed ≤0.05 MMD 
were grouped together in the second category, and all isolates from swine prescribed 
>0.05 MMD were grouped in the third category. 
When analyzing the tetracycline resistance in E. coli isolates for the human 
tetracycline class during the study period, the use was divided into 4 separate groups.  
The first group consisted of the isolates from the units prescribed MMDs ≤ 0.001 
(g/population at risk kg), the second group were all isolates with MMDs > 0.001 and ≤ 
0.002 (g/population at risk kg), the third group consisted of MMDs >0.002 and ≤ 0.004 
(g/population at risk kg) and the fourth group were all isolates > 0.004 (g/population at 
risk kg). 
Based on the histogram of the distribution of MMDs for the sulfonamide class in 
the human population, the MMDs were analyzed by 4 categories.  The first category 
consisted of isolates from units with MMDs of 0 (g/population at risk kg), the second 
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category had MMDs >0 and ≤ 0.002 (g/population at risk kg), the third category had 
MMDs > 0.002 and ≤ 0.004 (g/population at risk kg), and the final category had MMDs 
> 0.004 (g/individual at risk kg). 
The MMDs were grouped into 7 categories for the human penicillin class use 
during the period of January 2004 – January 2007.  The categories are as follows: 
category 1 consists of isolates from units with MMDs of ≤ 0.001 (g/population at risk 
kg), category 2 with MMDS of > 0.001 and ≤ 0.002 (g/population at risk kg), category 3 
with MMDs of > 0.002 and ≤ 0.003 (g/population at risk kg), category 4 with MMDs of 
> 0.003 and ≤ 0.004 (g/population at risk kg), category 5 with MMDs of > 0.004 and ≤ 
0.005 (g/population at risk kg), category 6 with MMDs of > 0.005 and ≤ 0.007 
(g/population at risk kg) and category 7 with MMDs of > 0.007 (g/population at risk kg). 
A histogram illustrating the MMDs for erythromycin use from January 2004 – 
December 2004 was constructed.  Based on the histogram, the MMDs for erythromycin 
in the human population were categorized into 3 categories: the first category consisted 
of isolates from units that prescribed MMDs 0 (g/population at risk kg), the second 
category of MMDs > 0 and ≤ 0.001 (g/population at risk kg), the third category of 
MMDs > 0.001 (g/population at risk kg). 
The MMD categories for the penicillin class use during January 2004-December 
2994 were obtained from a constructed histogram that illustrated the MMDs of penicillin 
class across all units.  The three categories are as follows: category 1 consisted of 
isolates from units with MMDs of ≤ 0.002 (g/population at risk kg), category 2 of 
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MMDs of > 0.002 and ≤ 0.004 (g/population at risk kg), category 3 of MMDs of > 0.004 
(g/population at risk kg). 
The relationships between the prevalence of resistant bacteria (dependent 
variable) and host species, human occupational exposure to swine, unit location, 
sampling period (i.e. month), and the level of antibiotic use (independent variable) were 
assessed with generalized estimating equations (GEE) in a generalized linear model 
(GLM) model framework using a binomial distribution and a logit function in STATA® 
ver. 9.2 (StataCorp, College Station, TX).  We built a model for each species resistance 
level based on antibiotic type and usage amount.  When calculating the odds ratios for 
the swine population, the estimates were adjusted by swine production group, antibiotic 
MMD, and season.  The estimates for the human population were adjusted by population 
at risk (i.e., non-worker or worker), MMD, and season.  In addition, the seasonal 
variation among E. coli and enterococci isolates were evaluated in a GLM model in 
order to assess possible seasonality during the period of January 2004 – January 2007. 
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CHAPTER IV 
RESULTS 
 
 E. coli Isolates  
There were 5,929 (2,715 human and 3,214 swine) commensal E. coli isolated 
from the swine fecal and human wastewater samples collected from January 2004 – 
January 2007.  During the period of 2004, the samples were analyzed monthly, but 
beginning in 2005 the samples were analyzed on a quarterly basis.  In order to have a 
uniform sampling scheme, the 2004 samples were collapsed into quarterly groups 
according to season (see Table 3, Appendix B). 
Tetracycline Resistance among Swine E. coli Isolates 
 Chlortetracycline (CTC) was the most commonly used antibiotic in the swine 
units from January 2004 – January 2007 (see Table 4, Appendix B).  It was used in all of 
the swine production groups (boars, gestating and farrowing females and piglets, 
grower/finishers, and nursery) (see Figure 3, Appendix A).  A histogram was constructed 
to illustrate the MMDs across all swine units during the study period (see Figure 4, 
Appendix A).  By using the three categories of MMDs, a dose response relationship with 
MMDs of CTC for isolates from each unit/month was identified among the E. coli 
isolates for tetracycline resistance.   The swine E. coli isolates were significantly (P < 
0.05) more likely to exhibit resistance to tetracycline at the highest MMD category 
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(adjusted OR = 1.81) when compared to the isolates collected from swine groups with 
zero-use of CTC (see Table 5, Appendix B). 
For this study, the chlortetracycline use and resistance level in each swine 
production group was also considered.    The gestation and farrowing females and piglets 
were used as the reference group in the statistical analysis since they represented the 
smallest percentage of swine across the units being prescribed CTC (previously 
illustrated in Figure 3, Appendix A).  The boars consisted of those in the farrow-
finishing units (n=5 units) and purchased from outside sources (i.e., held at the 
quarantine unit).  The grower/finisher (n=13) and nursery units (n=5; all at farrow-
finishing units) were also considered in this study. 
When considered by swine production group, the growers/finishers were 
prescribed the largest quantities of CTC during the period of January 2004 – January 
2007.  Although a smaller percentage of boars was prescribed CTC, E. coli isolated from 
the boars had statistically significant (P < 0.05) higher odds (adjusted OR = 1.51) of 
exhibiting tetracycline resistance than the reference swine category of gestating and 
farrowing females and piglets (see Table 6, Appendix B). 
In order to assess possible temporal patterns concerning tetracycline resistance 
among E. coli isolates in the swine population, the isolates were grouped by season and 
year.   No significant (P > 0.05) seasonality for the tetracycline resistance was observed 
during the study period (Figure 5, Appendix A). 
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Ceftiofur Resistance among Swine E. coli Isolates 
 Ceftiofur was used sparingly within the swine units and typically only in select 
pig production groups (see Figure 6, Appendix A).  A histogram was constructed in 
order to evaluate the overall use of ceftiofur in the swine units from January 2004 – 
January 2007 (Figure 7, Appendix A).  A very limited number of swine groups were 
prescribed ceftiofur; as a result, ceftiofur use in swine was considered in two categories: 
use versus nonuse (see Table 7, Appendix B). 
A non-significant (P = 0.282) association between monthly ceftiofur use and 
resistance was found among the swine E. coli isolates.  The E. coli from the swine that 
were housed in units during months that treatment with ceftiofur occurred had adjusted 
relative odds of 1.56 of exhibiting ceftiofur resistance (see Table 8, Appendix B).   
When the E. coli ceftiofur resistance was considered by production groups, the E. 
coli from the nursery group had a significantly elevated (P < 0.05) adjusted odds ratio of 
2.62 for exhibiting resistance (see Table 9, Appendix B).  The gestating and farrowing 
females and piglets had the highest proportion of ceftiofur use in the system, and 
although the nursery pigs had zero ceftiofur use during the study period, the nursery 
units had a significantly increased relative odds of ceftiofur resistance.  Ceftiofur was 
not used in the boars and a very low proportion of growers and finishers were prescribed 
ceftiofur.  
The seasonal variation in ceftiofur resistance among E. coli isolates was 
evaluated in a (GLM) model in order to assess possible seasonality during the period of 
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January 2004 – January 2007.  Although a higher proportion of ceftiofur resistant 
isolates qualitatively appeared in May 2004, no significant (P > 0.05) seasonal/cyclical 
trend was detected during the study period (see Figure 8, Appendix A). 
Tetracycline Resistance among Human E. coli Isolates 
The human therapeutic antibiotics considered in the tetracycline class were 
tetracycline and doxycycline.  In order to evaluate the use of antibiotics belonging to the 
tetracycline class in the human study population, a histogram was created to illustrate the 
tetracycline class use over the entire study period (see Figure 9, Appendix A). 
No significant (P > 0.05) association was identified for tetracycline MMD class 
and tetracycline resistance among E. coli in the overall human population (see Table 11, 
Appendix B).  When the population was categorized into swine-worker versus non-
worker groups, a nonsignificant (P > 0.05) difference in prevalence of tetracycline-
resistant E. coli between the two groups was observed.  From January 2004 – January 
2007, the non-agricultural workers were prescribed a higher proportion of antibiotics in 
the tetracycline class than workers (see Figure 10, Appendix A); however, it was the E. 
coli isolated from agricultural workers’ housing that exhibited a nonsignificant (P > 
0.05) higher adjusted relative odds (OR = 1.19, P = 0.126) of tetracycline resistance 
when compared to the nonworkers (see Table 12, Appendix B). 
 No significant (P > 0.05) seasonal/cyclical trends were observed when the 
resistant E. coli isolates were analyzed on a quarterly basis in a (GLM) model (see 
Figure 11, Appendix A). 
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Sulfonamide Resistance among Human E. coli Isolates 
 Antibiotics belonging to the sulfonamide class were used only in the human 
study population (see Table 13, Appendix B).  Based on the histogram of the distribution 
of MMDs for the sulfonamide class, the MMDs were analyzed by 4 categories (see 
Figure 12, Appendix A).  For the overall human population, no relationship was found 
for sulfonamide class use and sulfisoxazole resistance (see Table 14, Appendix B). 
The association of antibiotic use and resistance level was analyzed for the worker 
and non-worker groups (Figure 13, Appendix A).  The non-workers had a significantly 
(P < 0.05) higher adjusted relative odds (OR = 1.67) of exhibiting sulfisoxazole 
resistance during the study period than the swine-workers (see Table15, Appendix B).   
Despite the qualitative observation (see Figure 14, Appendix A) that the proportion of 
sulfisoxazole-resistant isolates appear to be elevated during the month of November 
2005, this increase did not represent a significant (P < 0.05) seasonal effect.   
 Ampicillin Resistance among Human E. coli Isolates 
In order to evaluate the relationship between the use of antibiotics belonging to 
the penicillin class and ampicillin and amoxicillin/clavulanic acid resistance, a histogram 
was created to assess the MMDs over the study period (see Figure 15, Appendix A). 
The majority of the isolates from the overall human study population were 
susceptible to ampicillin (see Table 16, Appendix B).  No (P > 0.05) relationship was 
found for penicillin class use and ampicillin resistance in the overall human population. 
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The nonagricultural workers had a higher percentage of patients in the population 
at risk who were prescribed an antibiotic belonging to the penicillin class than the 
worker category (see Figure 16, Appendix A).  When the relationship between the 
population at risk and ampicillin resistance was analyzed by a GEE equation, the 
nonworkers had a nonsignificantly (P > 0.05) adjusted higher odds (OR = 1.23) of 
harboring ampicillin resistant E. coli than the workers (see Table 18, Appendix B). 
No significant seasonal/cyclical trend was observed for ampicillin resistant 
isolates during the study period (see Figure 17, Appendix A). 
Amoxicillin/Clavulanic Acid Resistance among Human E. coli Isolates 
The majority of the human E. coli isolates collected from January 2004-January 
2007 were susceptible to amoxicillin/clavulanic acid (see Table 19, Appendix B).  Based 
on the histogram of MMD for penicillin class use across all units, the MMDs were 
considered in 7 categories when analyzing the relationship of amoxicillin/clavulanic acid 
resistance and penicillin class antibiotic prescribing practices.   
There was no relationship observed for penicillin class use and 
amoxicillin/clavulanic acid resistance during the study period (see Table 20, Appendix 
B).  As previously discussed, a higher proportion of the population at risk in the 
nonworker category were prescribed antibiotics belonging to the penicillin class than the 
population at risk in the worker category.  The E. coli from the nonworkers had a 
nonsignificantly (P > 0.05) higher adjusted odds (OR = 1.16) of exhibiting resistance to 
amoxicillin/clavulanic acid than the workers (see Table 21, Appendix B). 
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No significant (P > 0.05) seasonal/cyclical trend was observed for 
amoxicillin/clavulanic acid resistance during the study period (see Figure 18, Appendix 
A). 
Ciprofloxacin Resistance among Human E. coli Isolates 
 Ciprofloxacin was the only antibiotic in the flouroquinolone class that was used 
during the study period in the human population.  The MMD categories were created 
based on the observation from the histogram of MMD across all units from January 
2004-January 2007 (see Figure 19, Appendix A).  The MMDs for ciprofloxacin use were 
considered on a use versus nonuse basis for analysis in a GEE model. 
A very small proportion of the human E. coli isolates were resistant to 
ciprofloxacin (see Table 22, Appendix B).  A nonsignificant (P > 0.05) relationship was 
observed for ciprofloxacin use and resistance during the study period.  Although it was 
not statistically significant (P < 0.05), the E. coli from the population at risk in the units 
that prescribed ciprofloxacin had an adjusted higher odds (OR = 1.8, P = 0.317) of 
exhibiting resistance than the E. coli from the population at risk in units that did not 
prescribe ciprofloxacin (see Table 23, Appendix B). 
A higher proportion of nonworker cohorts were prescribed ciprofloxacin than 
agricultural worker cohorts in the human study population (see Figure 20, Appendix A).  
A nonsignificant (P > 0.05) relationship with ciprofloxacin use within the unit and E. 
coli from the population at risk category was observed.  E. coli from the population at 
risk in the worker category had a nonsignificant (P > 0.05) adjusted higher OR of 1.21 
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for ciprofloxacin resistance when compared to the nonworker category (see Table 24, 
Appendix B). 
No significant (P > 0.05) season/cyclical trend was observed for ciprofloxacin 
resistance in the human E. coli isolates (Figure 21, Appendix A). 
Enterococcus Spp. 
There were 669 (323 human, 346 swine) commensal enterococci isolated from 
the swine fecal and human wastewater samples collected from January 2004 – December 
2004.  The samples were collected and analyzed by month. 
Tylosin Resistance among Swine Enterococci Isolates 
The majority of the enterococci isolates exhibited tylosin resistance (see Table 
25, Appendix B).  A histogram of the tylosin MMDs was constructed in order to 
evaluate the range of values across the swine units (see Figure 22, Appendix A).  Tylosin 
use within the units was considered as use versus nonuse.  A significant (P < 0.05) 
relationship between tylosin use in the units and tylosin resistance was found.  
Enterococci from the units that prescribed enhanced feed containing tylosin had a 
statistically significant (P < 0.05) higher odds (OR = 3.54) of exhibiting tylosin 
resistance than the swine units with no tylosin use (see Table 26, Appendix B). 
Although the grower and finisher pigs were prescribed the largest amount of 
tylosin enhanced feed, the enterococci from the gestating and farrowing females and 
piglets had a significantly (P < 0.05) higher adjusted odds of tylosin resistance than the 
grower and finisher pigs (see Figure 23, Appendix A). The enterococci from the boar 
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and nursery units had a nonsignificantly (P > 0.05) higher adjusted odds (OR = 2.1, P = 
0.164 and OR = 1.6, P = 0.299) of exhibiting resistance than the farrowing units (see 
Table 27, Appendix B). 
No significant (P > 0.05) seasonal/cyclical trend was observed for tylosin 
resistance in the swine units during the study period (see Figure 24, Appendix A). 
Erythromycin Resistance among Swine Enterococci Isolates 
 A very small number of the swine isolates were sampled from pigs prescribed 
tilmicosin enhanced feed (see Table 28, Appendix B).  The MMDs for tilmicosin in 
swine were categorized as use versus nonuse based on the evaluation of the histogram 
which illustrated the MMDs of tilmicosin across all swine units (see Figure 25, 
Appendix A).  No relationship between tilmicosin use and erythromycin resistance was 
found in the isolates from the overall swine population. 
The nursery units were the only units that treated a few select pigs with 
tilmicosin (see Figure 26, Appendix A), but when the swine production categories were 
analyzed, the enterococci from the boar units had a statistically significant (P < 0.05) 
higher adjusted odds (OR = 3.5, p = 0.016) of erythromycin resistance than the 
farrowing units (see Table 29, Appendix B).  The enterococci from the nursery had a 
slightly higher adjusted odds (OR = 1.91, p = 0.147) but it was not statistically 
significant (P > 0.05). 
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When the resistant isolates were analyzed for seasonal/cyclical trend in the 
(GLM) model, no significant (P > 0.05) seasonal/cyclical trend was observed for 
erythromycin resistance during the study period (see Figure 27, Appendix A). 
Erythromycin Resistance among Human Enterococci Isolates 
 The majority of the human Enterococcus spp. isolates were susceptible to 
erythromycin (see Table 30, Appendix B).  In order to evaluate the relationship between 
erythromycin use and resistance, a histogram was constructed to show the MMDs of 
erythromycin across the human units (see Figure 28, Appendix A). 
No relationship between erythromycin use and resistance in the total human 
population was found (see Table 31, Appendix B).  A higher proportion of 
nonagricultural workers were prescribed erythromycin than the agricultural workers (see 
Figure 29, Appendix A).  The enterococci from the non-workers had a nonstatistically 
significant (P > 0.05) higher adjusted odds (OR = 3.79, p = 0.056) of harboring 
erythromycin resistant E. coli than workers (see Table 32, Appendix B). 
No significant (P > 0.05) seasonal trend was observed for erythromycin 
resistance in the enterococci isolates from January 2004 – December 2004 (see Figure 
30, Appendix A). 
Penicillin Resistance among Human Enterococci Isolates 
 The majority of the enterococci isolates were obtained from units where 
antibiotics belonging to the penicillin class were prescribed, but only a small proportion 
of those isolates were resistant to penicillin (see Table 33, Appendix B).  The MMD 
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categories were obtained from a constructed histogram that illustrated the MMDs of 
penicillin class across all units (see Figure 31, Appendix A). 
There was no relationship between penicillin resistance and use of antibiotics 
belonging to the penicillin class (see Table 34, Appendix B).  A higher proportion of 
nonworkers were prescribed antibiotics belonging to the penicillin class than the swine 
workers (see Figure 32, Appendix A).  The enterococci from the nonworkers had a 
nonsignificant (P > 0.05) higher adjusted odds (OR = 1.32, p = 0.531) of exhibiting 
penicillin resistance than workers (see Table 35, Appendix B). 
There was no significant (P > 0.05) seasonal trend observed for penicillin 
resistance during the study period (see Figure 33, Appendix A).  
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CHAPTER V 
DISCUSSION 
 
 In the present study E. coli and Enterococcus spp. were selected as surveillance 
organisms.  These commensal bacteria are generally considered to be good indicators 
due to their ability to serve as a reservoir for resistance genes and to transfer resistance 
to pathogenic bacteria (Witte, 1998; Winokur et al., 2001; Hayes et al., 2004; Scott et al., 
2005).  Also, E. coli and Enterococcus spp. are present in human wastewater and swine 
fecal samples in high concentrations and may be easily isolated (Huycke et al., 1998; 
Manero et al., 2006). 
Swine Resistance 
When the E. coli swine data were analyzed, relationships between antibiotic use 
and resistance within swine categories were observed.  The relationship between 
tetracycline resistance and MMD illustrated a dose-response association, with adjusted 
odds ratios (OR) of 1.20 and 1.81 (P < 0.05) for second and third categories of MMDs 
for chlortetracycline (CTC) use in medicated feed.  Odds ratios were adjusted for 
confounding effects of swine production group and season.  The variability in 
tetracycline resistance was somewhat explained by the variable levels of CTC use in 
feed, though resistance did not disappear in the absence of treatment.  This finding is 
consistent with other studies which found high levels of tetracycline resistant E. coli 
isolated from swine (Teshager et al, 2000; Schroeder et al, 2002b; Dewulf et al, 2007; 
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Stine et al, 2007).  Stine et al. (2007) studied the distribution of tetracycline resistance 
among bacteria isolated from a swine facility with a history of continual use of 
tetracycline-enhanced feed.  Of the E. coli isolates tested, 77% were resistant to 
tetracycline.  The present study demonstrated a baseline level of resistance among 
untreated animals at 81.7%.  The researchers in the Stine et al. (2007) study also found a 
significant difference in tetracycline resistant isolates present between isolates from feed 
hogs, houses, or lagoons and water or soil.  This indicates the increased chance of having 
resistant bacteria from exposure to swine and housing facilities and the need to obtain 
samples in order to assess this risk as is done in the present study.  
When broken down into groups, the boars had the highest relative odds of 
harboring tetracycline–resistant E. coli.  Although the grower and finisher units had the 
highest levels of chlortetracycline use, the boars had the highest odds of exhibiting 
resistant bacteria.  This finding is not in agreement with studies which found a higher 
level of resistance in younger pigs (Langlois et al., 1988; Matthew et al., 1999).  
Langlois et al. (1988) sampled, over a 20 month period, fecal matter from antibiotic-free 
pigs located in farrowing houses, finishing units, or on pasture.  A higher proportion of 
tetracycline-resistant isolates were obtained from pigs 6 months of age or less.  
However, in this present study, the oldest pigs in the system had the highest level of 
tetracycline resistance.  This may partially be due to purchasing boars from outside 
sources where the use of antibiotics is more prevalent.  By grouping the purchased boars 
with those housed in the system for longer periods of time, we had no antibiotic 
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treatment history for the purchased boars.  This may explain the higher level of 
resistance found in the boar population.  The boars are also in the system (up to 5 years 
old) longer than the pigs; typically the pigs are in the system (from birth to finish) an 
average of 6 months before going to slaughter.  Over this time, the boars have bred 
hundreds of sows and have been exposed to resistant bacteria in the manure and other 
body fluids whereas the finisher pigs have been exposed to at most 300 contemporary 
pigs during their lifetime. 
Ceftiofur was rarely used in the swine units; it was only used in units containing 
gestating and farrowing females and piglets.  A non-significant relationship between 
ceftiofur resistance and prescribing (OR = 1.56, P > 0.05) was found.  Ceftiofur was 
used to treat conditions in lactating sows that result in milk reduction and therefore 
affected growth performance in the piglets.  This antibiotic was also used to treat 
unweaned piglets for diarrheal diseases caused by E. coli.  The gestating and farrowing 
females and piglets had the highest proportion of ceftiofur use in the system, but the E. 
coli from the nursery units had a higher OR of 2.61 (p < 0.05) for exhibiting ceftiofur 
resistance than the farrowing units.  The higher odds in nursery pigs may result from 
piglets that were directly exposed to ceftiofur via injection or indirectly through 
treatment of their sow before moving into the nursery units.  In the swine E. coli, the 
baseline level of resistance to ceftiofur was 2.24%.  This finding is in agreement with 
another study that was conducted on pigs from Spanish slaughterhouses (Teshager et al., 
2000).  The fecal samples were collected from swine directly after slaughter and tested 
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for antibiotic susceptibility.  A low level of resistance to cephalothin was found (a 
separate antibiotic belonging to the cephalosporin class was used in the swine 
population).  The researchers only surveyed the resistance levels in a selected pig 
population without knowledge of corresponding antibiotic use.  This present study 
evaluated the antibiotic resistance in each swine category and also considered the 
amount of antibiotics used in each production category. 
Ceftiofur has been authorized for use in food animals for a relatively short period 
of time (first authorized in cattle in 1988), but plasmid-mediated resistance transfer 
between bacterial species has been reported (Winokur et al. 2001; Philippon et al., 2002; 
Batchelor et al., 2005).  Winokur et al. (2001) identified isolates of E. coli from bovine, 
swine, and humans that have the same CMY-2 B-lactamase.  Identical CMY-2 plasmids 
were also observed in E. coli and Salmonella isolates.  These findings suggest a transfer 
of resistance between bacterial species.  For this present study, only cephalosporin 
resistance was considered for the swine population; however, since the antibiotic 
utilization was calculated for the swine this important risk factor could be evaluated.  
Although ceftiofur resistance has developed in the food animal population, in this 
present study the baseline level of resistance is still very low. 
When the enterococci isolates were analyzed, a relationship between tylosin use 
and odds of tylosin resistance was observed.  The relationship between tylosin resistance 
and use in medicated feed was illustrated with an adjusted odds ratio (OR) of 3.54 (P < 
0.05).  This finding is in agreement with a study conducted in swine in the European 
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Union from 1998 to 2000 which found an association between tylosin use as a growth 
promoter and prevalence of resistance (Bywater et al., 2005).  After the first year of 
sampling, tylosin use as a growth promoter was discontinued.  As a result, differences in 
the prevalence of resistant strains were observed between year 1 and year 2 of the study.  
Bywater et al. (2005) only studied the prevalence of tylosin resistance across the two 
year period without assessing the dosage of tylosin given to the swine before the 
discontinuation of tylosin.  The boars and nursery units had higher odds of exhibiting 
resistance than the gestating and farrowing females and piglets, but the odds were not 
statistically significant.  Although the grower and finisher pig units consumed the most 
tylosin medicated feed from January 2004-January 2007, those units showed statistically 
significant (P < 0.05) lower odds of having isolates with tylosin resistance than the 
farrowing units.  The lower odds in the isolates from grower and finisher pigs may be 
explained by the short period of time the grower and finisher pigs were treated before 
slaughter and, as a result, the prevalence of resistant bacteria may be lower in the fecal 
matter. 
No relationship was found for use of tilmicosin medicated feed and erythromycin 
resistance during the period of January 2004 – December 2004.  When considered by 
swine production group, the isolates from boars had a statistically higher OR of 3.5 (P < 
0.05) of erythromycin resistance than the pigs in the farrowing buildings, but the nursery 
units were the only units given the medicated feed.  The isolates from nursery pigs only 
had slightly higher odds of erythromycin resistance.  The higher level of erythromycin 
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resistance in isolates from boars may be explained by the length of time spent in the 
system along with the possibility of previous antibiotic use from outside sources before 
purchase into the system. 
No seasonal trend was found for swine tetracycline, ceftiofur, tylosin, or 
erythromycin resistance.  This finding is not in agreement with the theory proposed by 
Moro et al. (2000) that changes in temperature affect the level of resistant isolates in 
swine at production facilities (Moro et al., 1998; Moro et al, 2000).  The researchers 
observed higher levels of resistant bacteria immediately following exposure to heat 
stress with a progressive drop in resistance after the exposure.  According to their theory, 
a higher proportion of resistant isolates should have been observed during the summer 
months (May and August), but no significant increase of the proportion of resistant 
isolates was found in this present study. 
Human Resistance 
 No relationship was found for tetracycline class use and tetracycline resistance in 
the overall human population, but when the population was categorized into 
worker/nonworker a modest nonsignificant (P > 0.05) difference between the two groups 
was observed.  Although, in this thesis, the proportion of nonworkers who were 
prescribed antibiotics belonging to the tetracycline class was much higher than the 
proportion of workers, the workers had a nonsignificantly higher OR of 1.19 (P > 0.05) 
of tetracycline resistance than the nonworkers.  This finding does not agree with a 
previous study that found a higher prevalence of tetracycline resistant bacteria in the 
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commensal flora of pig farmers (Aubry-Damon et al., 2004).  Aubry-Damon et al. 
(2004) selected 113 pig farmers and 113 nonfarmers with no antibiotic use within the 
past month.  Throat, nasal, and fecal swabs were obtained from the study participants 
only once during the study.  Unlike this present study, Aubry-Damon et al. relied on 
retrospective estimates of antibiotic use and one-time samples.  In this thesis, one 
possible explanation for the higher odds of resistance is that workers are in contact with 
more antibiotic resistant bacteria from the pigs.  Workers may come into contact with 
swine feces while directly handling the pigs or cleaning the stalls.  Also, the workers 
have contact direct contact with the antibiotics themselves during feed distribution to the 
swine.  During the feed distribution, the workers may breathe dust that is laden with 
antibiotic residue and thus may be given a small daily dose of chlortetracycline. 
The sulfonamides are commonly used to treat urinary tract infections caused by 
E. coli.  When the sulfonamide class effect on sulfisoxazole resistance was considered 
by worker/nonworker categories, the isolates from nonworkers had statistically 
significant (P < 0.05) higher odds of sulfixazole resistance than the workers.  This may 
be attributed to the higher percentage of nonworkers prescribed sulfonamides than 
workers.  The population at risk in the worker category may have fewer chronic 
illnesses, also known as the ‘healthy-worker’ effect.  The workers were also responsible 
for a much lower proportion of sulfonamide use than the nonworkers.   
In the human study population no statistically significant (P > 0.05) relationship 
between penicillin class MMDs and ampicillin or amoxicillin/clavulanic acid resistance 
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was observed.  The nonworkers were prescribed a higher percentage of those antibiotics 
belonging to the penicillin class than the workers.  Not surprisingly, a higher odds of 
ampicillin and amoxicillin/clavulanic acid resistance were observed in the isolates from 
the nonworker category.  A case-control study conducted by Hillier et al. (2007) in 
South Wales found a significant association of amoxicillin use and ampicillin resistance 
in patients with urinary tract infection.  Hillier et al. (2007) sampled patients from local 
general practices and surveyed the patients on previous antibiotic use within the previous 
year.  The population at risk with ampicillin-resistant E. coli were significantly more 
likely to have been prescribed ampicillin within the past year than the controls.  The 
study considered the risk of developing resistance in response to antibiotic use on the 
individual level, whereas in this present study the risk was assessed at the aggregate 
level; that is, the denominator included all housed individuals, whether prescribed 
antibiotics or not.  That said, our interest is at the ecological level. 
Ciprofloxacin belongs to the fluoroquinolone class; flouroquinolones are 
commonly used to treat urinary tract infections caused by E. coli.  E. coli may become 
resistant to flouroquinolones by mutating the target site and thus disabling the 
antibiotic’s ability to attach to the bacteria, or by efflux pumps which eject the antibiotic 
out of the cell (McDonald et al., 2001).  In this present study, no significant (P > 0.05) 
association between treatment with ciprofloxacin and resistance was observed and there 
was also not a statistically significant difference between worker and nonworker odds of 
ciprofloxacin resistance observed during the study period.  The findings of this present 
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study are not in agreement with a study conducted in Barcelona, Spain (Garau et al., 
1999).  Garau et al. (1999), found recent exposure to ciprofloxacin to be significantly 
associated with ciprofloxacin resistance in the human study population.  Although in this 
present study the majority of the nonworker population monthly cohorts were prescribed 
ciprofloxacin during the study period, no significant (P > 0.05) difference between the 
two groups was observed.   
 Traditionally, serious enterococcal infections have been treated with a 
combination of penicillins and aminoglycosides, but the emergence of resistance has led 
physicians to look for other treatments (Hodges et al., 1992).  One mechanism that 
enterococci employ for resistance to penicillins is the overproduction of low-affinity 
penicillin-binding proteins (Murray, 1998). When the enterococci human isolates were 
analyzed no relationship between erythromycin and penicillin use and resistance was 
found for the period of January 2004-December 2004.  The isolates from nonworkers 
had statistically significant (P < 0.05) higher adjusted odds of 3.58 of erythromycin 
resistance than the isolates from nonworkers which may be attributed to a higher 
percentage of use in nonworkers.   
 To the author’s knowledge this is the first study to have looked at resistance in 
relation to antibiotic use within an integrated agri-food system.  In the past, it has been 
difficult to establish a link between antibiotic consumption and the prevalence of 
resistance due to lack of antibiotic utilization records for human and swine populations 
in the study and also unlimited migration of study participants and lack of useful housing 
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cohort information.  By conducting this study in a relatively closed population with 
known antibiotic consumption and some with direct exposure to swine treated with 
antimicrobials, we have been able to address several questions concerning the 
relationship between use and resistance.  Also by considering the resistance and 
antibiotic use over a 3 year period at the same location we have provided insight into a 
possible seasonal/cyclical trend in antibiotic resistance levels.  The study populations 
were unique due to limited movement out of the system and across units.   Also the 
integration of the human and swine populations provided valuable insight into the 
possible links between occupational exposure and resistance.  While an increased odds 
of tetracycline resistance was found in agricultural workers, a causal association cannot 
be reached at this time.  Further study needs to be conducted to assess the resistance at 
intermediate breakpoints instead of only considering resistance versus susceptible 
outcomes.  
Study Limitations 
 One of the limitations to the swine portion of the study was the antibiotic 
utilization records.  Although monthly feed recipes were obtained from the feed mills in 
the system, the amount of antibiotic ingested by each pig was only an estimate.  Each 
unit recorded the feed and amount that was received from the feed mill but no record of 
the amount of feed that was dispensed was kept.  The production group prescribed an 
antibiotic and the duration of the treatment were estimated by experienced veterinarians 
from Texas A&M College of Veterinary Medicine and Biosciences.  Therefore, it was 
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assumed that all feed was properly dispensed to the swine in each unit.  Also, each pig 
was not individually weighed in order to calculate the MMDs.  The average weight of a 
pig in each separate category was estimated by an experienced swine veterinarian from 
Texas A&M College of Veterinary Medicine and Biosciences.  For the injectable 
antibiotics, only the records of the vials sent to the units were available for this study.  
Therefore, we assumed that all of the vials were used within the month they were sent to 
each unit. 
For the human portion of the study, the swine workers and nonworkers were 
analyzed separately.  The records of the population at risk categories only provided the 
worker/nonworker status.  The various jobs for the workers were not provided, therefore 
all of the workers were considered as having contact with the swine if they were located 
in units with swine facilities.  Another limitation to this study was the antibiotic 
utilization records.  The records only recorded the amount dispensed from the central 
pharmacy and for the purposes of this study we assumed each individual took the entire 
prescription.   
For the purposes of this thesis, only the outcome of resistant bacteria versus 
susceptible bacteria was considered.  The breakpoints used when evaluating the 
phenotypic characterization for E. coli and enterococci were obtained from the Clinical 
Laboratory Standards Institute.  Although this method provided insight into the 
prevalence of resistance, this may provide a limitation to this study by not considering 
the actual minimal inhibitory concentration values.  
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CHAPTER VI 
CONCLUSIONS 
 
Summary and Conclusions  
Our study showed that risk of tetracycline, ceftiofur, and tylosin resistance in 
bacteria from swine is dependent on CTC, ceftiofur, and tylosin use, respectively.  The 
swine production cycle effect on the risk of tetracycline, ceftiofur, tylosin, and 
erythromycin resistance is also important.  The study indicated that risk of tetracycline 
resistance in human bacterial isolates may be associated with exposure to swine.  Also, 
the temporal/seasonal effects on the risks of resistance for the antimicrobials studied in 
this project were not important.   
This study provides a better understanding of the relationships between antibiotic 
prescribing practices at the ecologic level and the relative risks of transmission of 
resistant bacteria within host species in a vertically integrated agri-food system. 
Recommendations for Future Studies 
 Resistant organisms are becoming increasingly common , and these resistant 
bacteria are responsible for increased morbidity and mortality as a result of treatment 
failures.  Not only are resistant bacteria a problem in healthcare facilities, but also in the 
community.  Cases with resistant bacteria are reported from sports teams, child daycares, 
and military personnel.  A financial strain has been placed on the healthcare system with 
the added stress of infection containment in health facilities, costly use of antibiotics, 
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and development of new antibiotics for future use.  There is an urgent need to better 
understand the transmission dynamics of resistant bacteria between food animals and 
humans.  In order to achieve that goal, future studies should further assess antimicrobial 
usage in human and swine populations by obtaining drug utilization records instead of 
relying on rough estimates of usage.  Also, records of the movement of humans across 
the categories of worker/nonworkers should be kept in order to track the exposure time 
to the swine.  Finally, a study considering intermediate resistant breakpoints or actual 
minimal inhibitory concentrations of antibiotics would provide valuable insight for 
determining prevalence of resistance at intermediate levels. 
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APPENDIX A 
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Figure 1. Antibiotic dispensing method within the human study population. 
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Figure 2. Antibiotic dispensing method within the swine study population. 
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Figure 3. Chlortetracycline mean monthly dosages distributed among the swine production 
categories. 
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Figure 4. Chlortetracycline use across all swine units from January 2004-January 2007. 
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Figure 5. The proportion of swine tetracycline resistant Escherichia coli isolates collected from 
February 2004 – November 2006. 
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Figure 6. Ceftiofur use distributed among the swine categories from January 2004- January 
2007. 
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Figure 7. Ceftiofur use across all swine units from January 2004-January 2007. 
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Figure 8. The proportion of ceftiofur resistant swine Escherichia coli isolates sampled from 
February 2004 – November 2006. 
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Figure 9. The human tetracycline class use across all units from January 2004-January 2007. 
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Figure 10. Tetracycline class use distributed among the human categories. 
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Figure 11. The proportion of tetracycline resistant human Escherichia coli isolates sampled from 
February 2004 – November 2006. 
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Figure 12. The human sulfonamide class use across all units from January 2004-January 2007.  
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Figure 13. Sulfonamide class use distributed among the human categories. 
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Figure 14. The proportion of sulfisoxazole resistant human Escherichia coli isolates sampled 
from February 2004 – November 2006. 
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Figure 15. The human penicillin class use across all units during the period of January 2004-
January 2007. 
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Figure 16. Penicillin class use distributed among human categories. 
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Figure 17. The proportion of ampicillin resistant human Escherichia coli isolates sampled from 
January 2004-January 2007. 
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Figure 18. The proportion of amoxicillin/clavulanic acid resistant human Escherichia. coli 
isolates from February 2004-November 2006. 
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Figure 19. The human ciprofloxacin class mean monthly dosages across all units during the 
period of January 2004-January 2007. 
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Figure 20. Ciprofloxacin use distributed among human categories. 
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Figure 21. Proportion of ciprofloxacin resistant human Escherichia coli isolates from February 
2004-November 2006. 
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Figure 22. The swine tylosin mean monthly dosages across all units during the period of January 
2004-December 2004. 
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Figure 23. Tylosin use distributed across swine production groups. 
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Figure 24. Proportion of tylosin resistant swine Enterococcus spp. isolates from January 2004-
December 2004. 
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Figure 25. The swine tilmicosin mean monthly dosages across all units during the period of 
January 2004-December 2004. 
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Figure 26. Tilmicosin use distributed among the swine production categories from January 2004-
December 2004. 
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Figure 27. The proportion of erythromycin resistant swine Enterococcus spp. isolates sampled 
from January 2004-December 2004. 
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Figure 28. Erythromycin use across all human units from January 2004-December 2004. 
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Figure 29. Erythromycin use distributed among the human categories. 
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Figure 30. The proportion of erythromycin resistant human Enterococcus spp. isolates samples 
from January 2004-December 2004. 
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Figure 31. The penicillin class use across all human units from January 2004-December 2004. 
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Figure 32. Penicillin class use distributed among the human categories. 
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Figure 33. The proportion of penicillin resistant human Enterococcus spp. isolates sampled from 
January 2004-December 2004. 
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APPENDIX B 
 
Table 1. Interpretation criteria of 15 antibiotics tested against Escherichia coli. 
Antibiotic  Range Tested Resistant Breakpoint 
Amikacin 0.5 – 64 ≥64 
Ampicillin 1 – 32 ≥32 
Amoxicillin/Clavulanic Acid 1/0.5 – 32/16 ≥32/16 
Cefoxitin 0.5 – 32 ≥32 
Ceftiofur 0.12 – 8 ≥8 
Ceftriaxone 1 – 64 ≥64 
Chloramphenicol 2 – 32 ≥32 
Ciprofloxacin 0.015 – 4 ≥4 
Gentamicin 0.25 – 16 ≥16 
Kanamycin 8 – 64 ≥64 
Nalidixic Acid 0.5 – 32 ≥32 
Streptomycin 32 – 64 ≥64 
Sulfisoxazole 16 – 512 ≥512 
Tetracycline 4 – 32 ≥32 
Trimethoprim/Sulphamethoxazole 0.12 – 4 ≥4 
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Table 2. Interpretation criteria of 17 antibiotics tested against Enterococcus spp. 
Antibiotic Range Tested Resistant Breakpoint 
Bacitracin 8 – 128 ≥128 
Chloramphenicol 2 – 32 ≥32 
Ciprofloxacin 0.5 – 8 ≥8 
Daptomycin 0.5 – 16 ≥8 
Erythromycin 0.12 – 4 ≥4 
Flavomycin 1 – 32 ≥32 
Gentamicin 128 – 1024 ≥500 
Kanamycin 128 – 1024 ≥512 
Lincomycin 1 – 32 ≥32 
Linezolid 0.5 – 8 ≥8 
Nitrofurantoin 2 – 64 ≥128 
Penicillin 0.5 – 16 ≥16 
Streptomycin 512 – 2048 ≥1000 
Quinupristin/ dalfopristin 1 – 32 ≥4 
Tetracycline 4 – 32 ≥16 
Tylosin tartrate 0.25 – 32 ≥32 
Vancomycin 0.5 – 32 ≥32 
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Table 3. The 2004 Escherichia coli isolates grouped according to season. 
Month Months collapsed 
  
February February 
 March 
 April 
  
May May 
 June 
 July 
  
August August 
 September 
 October 
  
November November 
 December 
 January 
 
 
 
 
 
   87
 
  
Table 4. Swine Escherichia coli isolates collected from January 2004-January 2007 grouped by 
tetracycline resistance category and chlortetracycline mean monthly dosages. 
Chlortetracycline 
MMD (g/pig kg) 
Tetracycline 
Susceptible 
Tetracycline 
Resistant 
Total 
0 316 (18.09 %) 1,431 (81.91 %) 1,747 
    
>0 and ≤ 0.05 88 (16.18 %) 456 (83.82 %) 544 
    
> 0.05  62 (6.72 %) 861 (93.28 %) 923 
 
 
Table 5. The adjusted odds ratios for swine feces harboring tetracycline-resistant E. coli in 
relation to chlortetracycline mean monthly dosage. 
Chlortetracycline 
MMD (g/pig kg) 
Odds Ratio Standard Error z P>|z| 95% Confidence 
Interval 
0 1.0     
      
>0 and ≤ 0.05 1.20 0.186 1.18 0.239 0.885, 1.626 
      
> 0.05 1.81 0.26 4.16 0.000 1.37, 2.40 
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Table 6. The adjusted odds ratios for harboring tetracycline-resistant E. coli in each swine 
production group. 
Swine Production 
Groups 
Odds Ratio Standard Error z P>|z| 95% Confidence 
Interval 
Farrowing 1.0     
      
Boars 1.51 0.255 2.47 0.014 1.09, 2.11 
      
Grower & Finisher 1.24 0.175 1.58 0.115 0.948, 1.644 
      
Nursery 1.38 0.277 1.61 0.106 0.933, 2.05 
 
 
Table 7. Swine Escherichia coli isolates collected from January 2004-January 2007 grouped by 
ceftiofur use and susceptibility. 
Ceftiofur Use (g/pig 
kg) 
Ceftiofur 
Susceptible 
Ceftiofur 
Resistant 
Total 
No 2876 (97.76%) 66 (2.24%) 2,942 
    
Yes 261 (95.96%) 11 (4.04%) 272 
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Table 8. The adjusted odds ratios for harboring ceftiofur–resistant E. coli when ceftiofur was 
prescribed to the swine in the study. 
Ceftiofur Use Odds Ratio Standard Error z P>|z| 95% Confidence 
Interval 
No 1.0     
      
Yes 1.56 0.649 1.08 0.282 0.692, 3.53 
 
 
Table 9. The adjusted odds ratios for harboring ceftiofur–resistant E. coli in each swine 
production category. 
Ceftiofur Use Odds Ratio Standard Error z P>|z| 95% Confidence Interval 
Farrowing 1.0     
      
Boars 0.179 0.115 -2.66 0.008 0.051, 0.636 
      
Grower & 
Finisher 
0.663 0.228 -1.20 0.231 0.033, 1.299 
      
Nursery 2.61 0.931 2.70 0.007 1.303, 5.255 
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Table 10. Human Escherichia coli isolates collected from January 2004-January 2007 grouped 
by tetracycline class use and tetracycline resistance. 
Tetracycline Class 
MMD (g/at risk 
population 
kg*month) 
Tetracycline 
Susceptible 
Tetracycline 
Resistant 
Total 
0 – 0.001  539 (76.56 %) 165 (23.44 %) 704 
    
>0.001 and ≤ 0.002 676 (82.54 %) 143 (17.46 %) 819 
    
> 0.002 and ≤ 0.004 431 (79.08 %) 114 (20.92 %) 545 
    
> 0.004  151 (82.97 %) 31 (17.03 %) 182 
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Table 11. The adjusted odds ratios for harboring tetracycline–resistant E. coli in human study 
population in relation to tetracycline class use. 
Tetracycline Class 
MMD (g/at risk 
population 
kg*month) 
Odds Ratio Standard Error z P>|z| 95% Confidence 
Interval 
0 – 0.001 1.0     
      
>0.001 and ≤ 0.002 0.689 0.093 -2.76 0.006 0.529, 0.897 
      
> 0.002 and ≤ 0.004 0.943 0.146 -0.38 0.706 0.696, 1.278 
      
> 0.004  0.694 0.173 -1.46 0.144 0.426, 1.133 
 
 
Table 12. The adjusted odds ratio for harboring tetracycline–resistant E. coli in the human 
population at risk category. 
Tetracycline Class 
Resistance 
Odds Ratio Standard Error z P>|z| 95% Confidence 
Interval 
Nonworker 1.0     
      
Worker 1.19 0.140 1.53 0.126 0.951, 1.51 
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Table 13. Human Escherichia coli isolates collected from January 2004-January 2007 grouped 
by sulfisoxazole resistance and sulfonamide class use. 
Sulfonamide Class 
MMD (g/at risk 
population kg*month) 
Sulfisoxazole 
Susceptible 
Sulfisoxazole 
Resistant 
Total 
0 698 (85.64 %) 117 (14.36 %) 815 
    
> 0 and ≤ 0.002 673 (84.87 %) 120 (15.13 %) 793 
    
> 0.002 and ≤ 0.004 355 (84.73 %) 64 (15.27 %) 419 
    
> 0.004 202 (90.58 %) 21 (9.42 %) 223 
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Table 14. The adjusted odds ratios for harboring sulfisoxazole–resistant E. coli in the human 
study population when an antibiotic belonging to the sulfonamide class is prescribed. 
Sulfonamide Class 
MMD (g/at risk 
population 
kg*month) 
Odds Ratio Standard Error z P>|z| 95% Confidence 
Interval 
0 1.0     
      
> 0 and ≤ 0.002 0.756 0.129 -1.63 0.102 0.541, 1.057 
      
> 0.002 and ≤ 0.004 0.823 0.149 -1.07 0.285 0.576, 1.176 
      
> 0.004 0.432 0.103 -3.53 0.000 0.271, 0.688 
 
 
Table 15. The adjusted odds ratios for harboring sulfisoxazole–resistant E. coli in the human 
categories. 
Sulfonamide Class 
Resistance 
Odds Ratio Standard Error z P>|z| 95% Confidence 
Interval 
Worker 1.0     
      
Nonworker 1.67 0.265 3.27 0.001 1.229, 2.283 
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Table 16. Human Escherichia coli isolates collected from January 2004-January 2007 grouped 
by ampicillin resistance and penicillin class use. 
Penicillin Class 
MMD (g/at risk 
population 
kg*month) 
Ampicillin  
Susceptible 
Ampicillin 
Resistant 
Total 
≤ 0.001 274 (86.71 %) 42 (13.29 %) 316 
    
> 0.001 and ≤ 0.002 528 (82.50 %) 112 (17.50 %) 640 
    
> 0.002 and ≤ 0.003 573 (88.29 %) 76 (11.71 %) 649 
    
> 0.003 and ≤ 0.004 352 (83.22 %) 71 (16.78 %) 423 
    
> 0.004 and ≤ 0.005 257 (84.26 %) 48 (15.74 %) 305 
    
> 0.005 and ≤ 0.007 248 (76.54 %) 76 (23.46 %) 324 
    
> 0.007 41 (83.67 %) 8 (16.33 %) 49 
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Table 17. The adjusted odds ratios for harboring ampicillin–resistant E. coli in relation to 
penicillin class antibiotic prescribing practices in the human study population. 
Penicillin Class Use 
MMD (g/at risk 
population 
kg*month) 
Odds Ratio Standard Error z P>|z| 95% Confidence 
Interval 
≤ 0.001 1.0     
      
> 0.001 and ≤ 0.002 1.43 0.325 1.58 0.115 0.916, 2.232 
      
> 0.002 and ≤ 0.003 0.81 0.200 -0.84 0.403 0.502, 1.318 
      
> 0.003 and ≤ 0.004 1.19 0.303 0.71 0.477 0.729, 1.965 
      
> 0.004 and ≤ 0.005 1.25 0.327 0.86 0.388 0.751, 2.091 
      
> 0.005 and ≤ 0.007 2.22 0.542 3.26 0.001 1.375, 3.583 
      
> 0.007 1.39 0.704 0.65 0.515 0.515, 3.753 
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Table 18. The adjusted odds ratios for harboring ampicillin–resistant E. coli by population at risk 
category. 
Ampicillin 
Resistance 
Odds Ratio Standard Error z P>|z| 95% Confidence 
Interval 
Worker 1.0     
      
Nonworker 1.23 0.158 1.65 0.098 0.961, 1.589 
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Table 19. Human Escherichia coli isolates collected from January 2004-January 2007 grouped 
by amoxicillin resistance and penicillin class use. 
Penicillin Class Use 
(g/at risk population 
kg*month) 
Amoxicillin/Clavulanic 
Acid Susceptible 
Amoxicillin/Clavulanic 
Acid Resistant 
Total 
≤ 0.001 310 (98.10 %) 6 (1.90 %) 316 
    
> 0.001 and ≤ 0.002 624 (97.5 %) 16 (2.5 %) 640 
    
> 0.002 and ≤ 0.003 637 (98.15 %) 12 (1.85 %) 649 
    
> 0.003 and ≤ 0.004 411 (97.16 %) 12 (2.84 %) 423 
    
> 0.004 and ≤ 0.005 298 (97.70 %) 7 (2.3 %) 305 
    
> 0.005 and ≤ 0.007 316 (97.53 %) 8 (2.47 %) 324 
    
> 0.007 48 (97.96 %) 1 (2.04 %) 49 
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Table 20. The adjusted odds ratios for harboring amoxicillin/clavulanic acid-resistant E. coli in 
relation to use of antibiotic belonging to the penicillin class. 
Penicillin Class Use 
(g/at risk 
population 
kg*month) 
Odds Ratio Standard Error z P>|z| 95% Confidence 
Interval 
≤ 0.001 1.0     
      
> 0.001 and ≤ 0.002 2.11 1.125 1.41 0.160 0.745, 5.99 
      
> 0.002 and ≤ 0.003 1.015 0.594 0.03 0.980 0.323, 3.194 
      
> 0.003 and ≤ 0.004 1.795 1.04 1.01 0.313 0.576, 5.591 
      
> 0.004 and ≤ 0.005 1.679 1.01 0.86 0.389 0.516, 5.461 
      
> 0.005 and ≤ 0.007 1.588 0.946 0.78 0.438 0.494, 5.106 
      
> 0.007 1.984 2.204 0.62 0.537 0.225, 17.49 
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Table 21. The adjusted odds ratios for harboring amoxicillin/clavulanic acid-resistant E. coli in 
relation to population at risk category. 
Penicillin 
Resistance 
Odds Ratio Standard Error z P>|z| 95% Confidence 
Interval 
Worker 1.0     
      
Nonworker 1.17 0.343 0.54 0.592 0.659, 2.078 
 
 
 
Table 22. Human Escherichia coli isolates collected from January 2004-January 2007 grouped 
by ciprofloxacin use and resistance. 
Ciprofloxacin Use  Ciprofloxacin 
Susceptible 
Ciprofloxacin 
Resistant 
Total 
No 1,901 (95.24 %) 10 (4.76 %) 1,911 
    
Yes 796 (97.75 %) 7 (2.25 %) 803 
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Table 23. The adjusted odds ratios for harboring ciprofloxacin–resistant E. coli in the human 
isolates in relation to ciprofloxacin use within units. 
Ciprofloxacin Use Odds Ratio Standard Error z P>|z| 95% Confidence 
Interval 
No 1.0     
      
Yes 1.81 1.06 1.0 0.317 0.568, 5.737 
 
 
Table 24. The adjusted odds ratios for harboring ciprofloxacin–resistant E. coli in relation to 
population at risk category. 
Ciprofloxacin 
Resistance 
Odds Ratio Standard Error z P>|z| 95% Confidence 
Interval 
Nonworker 1.0     
      
Worker 1.21 0.701 0.34 0.732 0.395, 3.76 
 
 
Table 25. Swine Enterococcus spp. isolates collected from January 2004-December 2004 
grouped by tylosin resistance and use. 
Tylosin Use  Tylosin Susceptible Tylosin Resistant Total 
No 144 (46.91 %) 163 (53.09%) 307 
    
Yes 7 (17.95 %) 32 (82.05 %) 39 
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Table 26. The adjusted odds ratios for harboring tylosin–resistant enterococci in relation to swine 
tylosin use. 
Tylosin 
Use 
Odds Ratio Standard Error z P>|z| 95% Confidence 
Interval 
No 1.0     
      
Yes 3.54 1.656 2.70 0.007 1.415, 8.855 
 
 
 
 
Table 27. The adjusted odds ratios for harboring tylosin-resistant enterococci in relation to swine 
production groups. 
Tylosin Use Odds Ratio Standard Error z P>|z| 95% Confidence Interval 
Farrowing 1.0     
      
Boars 2.13 1.158 1.39 0.164 0.735, 6.18 
      
Grower & 
Finisher 
0.451 0.112 -3.21 0.001 0.277, 0.733 
      
Nursery 1.60 0.729 1.04 0.299 0.658, 3.908 
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Table 28. Swine Enterococcus spp. isolates collected from January 2004-December 2004 
grouped by tilmicosin use and erythromycin resistance. 
Tilmicosin Use  Erythromycin 
Susceptible 
Erythromycin 
Resistant 
Total 
No 149 (43.57 %) 193 (56.43 %) 342 
    
Yes 0 4 4 
 
 
 
Table 29. The adjusted odds ratios for harboring erythromycin–resistant enterococci in relation 
to swine production groups. 
Tilmicosin Use Odds Ratio Standard Error z P>|z| 95% Confidence Interval 
Farrowing 1.0     
      
Boars 3.5 1.82 2.41 0.016 1.266, 9.686 
      
Grower & 
Finisher 
0.62 0.149 -1.99 0.047 0.388, 0.993 
      
Nursery 1.91 0.857 1.45 0.147 0.796, 4.605 
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Table 30. Human Enterococcus spp. isolates collected from January 2004-December 2004 
grouped by erythromycin use and erythromycin resistance.  
Erythromycin MMD 
(g/at risk population 
kg*month) 
Erythromycin 
Susceptible 
Erythromycin 
Resistant 
Total 
0 59 (96.72%) 2 (3.28%) 61 
    
> 0 and ≤ 0.001 204 (95.33 %) 10 (4.67 %) 214 
    
> 0.001 47 (97.92 %) 1 (2.08 %) 48 
 
 
 
Table 31. The adjusted odds ratios for harboring erythromycin-resistant enterococci in human 
isolates in relation to erythromycin use. 
Erythromycin 
Resistance (g/at 
risk population 
kg*month) 
Odds Ratio Standard Error z P>|z| 95% Confidence 
Interval 
0 1.0     
      
> 0 and ≤ 0.001 0.718 0.587 -0.40 0.685 0.145, 3.56 
      
> 0.001 0.405 0.522 -0.70 0.483 0.0323, 5.071 
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Table 32. The adjusted odds ratios for harboring erythromycin–resistant enterococci in relation 
to population at risk category. 
Erythromycin 
Resistance 
Odds Ratio Standard Error z P>|z| 95% Confidence 
Interval 
Worker 1.0     
      
Nonworker 3.79 2.65 1.91 0.056 0.967, 14.89 
 
 
Table 33. Human Enterococcus spp. isolates collected from January 2004-December 2004 
grouped by penicillin class use and penicillin resistance. 
Penicillin class MMD 
(g/at risk population 
kg*month) 
Penicillin 
Susceptible 
Penicillin 
Resistant 
Total 
≤ 0.002 122 (87.77 %) 17 (12.23 %) 139 
    
> 0.002 and ≤ 0.004 124 (91.85 %) 11 (8.15 %) 135 
    
> 0.004 47 (95.92 %) 2 (4.08 %) 49 
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Table 34. The adjusted odds ratios for harboring penicillin–resistant enterococci in human 
isolates in relation to use of antibiotics belonging to the penicillin class. 
Penicillin 
Resistance (g/at 
risk population 
kg*month) 
Odds Ratio Standard Error z P>|z| 95% Confidence 
Interval 
≤ 0.002 1.0     
      
> 0.002 and ≤ 0.004 0.654 0.281 -0.99 0.323 0.282, 1.518 
      
> 0.004 0.334 0.257 -1.42 0.154 0.074, 1.509 
 
 
 
Table 35. The adjusted odds ratios for harboring penicillin–resistant enterococci in human 
isolates in relation to population at risk category. 
Penicillin 
Resistance 
Odds Ratio Standard Error z P>|z| 95% Confidence 
Interval 
Worker 1.0     
      
Nonworker 1.33 0.532 0.71 0.479 0.606, 2.909 
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